Annexon, Inc. (ANNX) Discusses Vision Preservation in Geographic Atrophy With C1q Inhibition and Key Insights From ARCHER Trials - Slideshow

Annexon presented clinical insights on its C1q inhibitor therapy for geographic atrophy (GA), a leading cause of blindness, during a March 2026 corporate update. The ARCHER trials demonstrated vision preservation potential by targeting the classical complement pathway, specifically C1q, to slow retinal degeneration in GA patients. Key data highlighted reduced lesion growth and functional vision benefits, suggesting C1q inhibition may outperform existing treatments like anti-VEGF therapies. The company emphasized its pipeline’s differentiation, with ongoing Phase 3 trials aiming to validate long-term efficacy and safety in GA and other complement-driven diseases. Investor focus centered on regulatory milestones, with Annexon targeting FDA submissions by late 2027 if trial endpoints are met.